CANCER.
Information on current developments in both regular and alternative or complementary treatments for cancer types and resources at all stages. We have basically all articles and information put in alphabetical order, scroll in left column in alphabetical list.
Experiences of cancer patients with complementary approaches can be found by experience stories and there are also some videos of experiences of cancer patients to see. To click on video button top left . Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Cemitidine (product name Tagamet-800), originally an inhibitor of gastric acid in stomach and colon cancer proves an effective cancer inhibitor to be spectacular.
As early as January in the British Journal of Oncology study published below. To my knowledge, this information by few other media picked up, while the results are absolutely spectacular to mention. Giving Cemitidine (product name Tagamet-800) was launched two weeks after surgery and a year later given to 64 cancer patients in order to see what would be the effect on survival and regression of the disease. In this study, a difference of less than ten years survival of 84.6% versus 49.8% in the control measure. A difference of 35 %!!!! Endorsement: these results were measured in cancer patients with high sialyl Lewis X and Lewis-A values, which I do not know but your doctor is very determined. "It's not yet clear whether patients with low values possibly even a negative effect in, results were indeed not significant but still be careful." So it is this well with your doctor / oncologist to discuss and not on your own this plea use. It is a remarkable and important research because colon cancer as the biggest risk is the recurrence (regression) because there is often of tiny metastases that new tumors. On the website of LEF Magasin you can read many more - many more studies have been run from the seventies - Cemitidine on this ground, even in gastric cancer patients. Today we dated June 29, 2002 a Dutch translation of Luuk wrote this article below. Below the following original English article references a number of articles and studies on Cemitidine. More information for gastric cancer patients on page cancers, stomach cancers.dated June 29, 2002: Source Pubmed: Luuk translation, English original article in this translation.
Cemitidine (brand name Tagamet) is an agent traditionally used to combat stomach acid. Published research over 20 years ago shows that this means much more for the medical community can do, if it would be used for cancer therapy than as a remedy for stomach ailments.
Since Cemitidine being known as a remedy for heartburn, is its role in cancer treatment grossly overlooked. The same thing happened when aspirin was first recommended to prevent a heart attack, doctors were so used to prescribe aspirin as a remedy for pain and burning, but unfamiliar with taking aspirin for heart muscle disease and thrombosis. Now is the standard to be prescribed for a heart attack, as long as no individual contra-indications.
To date, the proven qualities of Cemitidine cancer treatment has been discovered in the medical world. The results of a brand new investigation of patients with colorectal cancer may provide sufficient evidence to convince oncologists that Cemitidine an effective additional treatment.
In the following article we discuss the anti-cancer benefits of Cemitidine and at what kinds of cancer Cemitidineeffectief proved. The brand name for Cemitidine Tagemet is, what a drug prescription.
The first investigation, which revealed a Cemitidine effective against cancer could be published in late 1970. Scientists first thought it worked by enhancing the immune system. Later studies showed that Cemitidine works in different ways to enhance tumor metastasis and to prevent it. In 1988, in a randomized, double-blinded study the effect of Cemitidinegehouden to the survival of 181 patients with gastric cancer. They received 2 x 400 mg Cemitidine daily or placebo for a period of 2 years or until death. The study found that those who provide Cemitidine had received, had a remarkably prolonged survival, especially in patients with stage II and IV cancer. This result is especially remarkable in light of what we nowadays know about Cemitidine.
In 1994, a survey which found that one of only seven days with Cemitidine (five days before surgery and 2 days after) the number in three years dead patients with rectal cancer decreased from 41% to 7%. Another phenomenon was that the tumors of treated patients had a significantly higher pentratienivo of lymfociten. This tumor invading lymfociten are a good indicator because they are part of the immune system response to the tumor. With a higherlymfociten share, present in the tumor, the body is better able to attack the tumor and off. This observation is in the medical community led to the proposition that Cemitidine functions as enhancing the immune system response in some areas.
The latest study, published in the British Journal of Cancer, January 2002, was conducted by a collaboration of 15 Japanese institutes. After surgery to remove the primary tumor, followed by IV Mitocymin chemotherapy, all patients received daily either 200 mg of orally administered 5-FU 200 mg either orally administered 5-FU 800 mg orally administered Cemitidine for 12 consecutive months. Patients were observed for 10 years. The study showed a more than threefold improvement in 10-year survival rate of patients with colon cancer, type C. Duke Striking is the observation that the less aggressive colon cancers Duke A and B not responded remarkably well to the administration of Cemitidine as the more aggressive cancer Duke CE.
How does Cemitidine.
Cemitidine is an active inhibitor of the histamine receptors on the cells of the stomach acid that hide. Cemitidine binds to these so-called H2 receptor and prevents histamine does. Histamine is responsible for turning on the H2 receptors hiding acid. Cemitidine If present, the receptors are not induced to acid production and thus reduced the zuurtenivo in the stomach.
Patients with cancer who want to know whether Cemitidine with them would benefit, should ask for a laboratory examination of their tumor on the so-called "Lewis antigen expression. Lewis X and Lewis A antibodies to {} cell surface ligands on cancer cells, which attach to molecules found in blood vessels, called E-selection. The attachments of cancer cells to E-selectin on blood vessels encourages the dissemination process.
In one study estimated that 70% of colon cancers a high number of these antibodies to have Lewis. Also, breast and pancreatic cancer have proven to have these antibodies. Now Cemitidine bonding E-selectin inhibits blood vessel, cancer cells can enter the bloodstream with Lewis X and Lewis A Antibody no longer attach to the blood vessels and thus no longer care for dissemination of the tumor.
The U.S. laboratory where the test can be carried IMPATH Laboratories, 521 West 57th Street, New York, Tel: 1-800-447-5816.
Cemitidine since 1975 used for stomach complaints. Before that it was also prescribed for nausea, caused by chemotherapy, to treat. In 1988 it was found that patients with colorectal cancer, for Ci. dosed, responded significantly better than those who received no Cemitidine. Many hypotheses have been suggested to explain this phenomenon. Since Cemitidine known as histamine receptor antagonist, was suspected that the effect was due to this. Histamine is thus one of the components that the body blocked to prevent the immune response. Histamine can be released into the environment of the tumor and prevent the immune system's tumor falls. Cemitidine If this mechanism works against, the immune system are in a position to an effective response to the tumor, ie, the cancer attacks. It may be one of the processes, along Cemitidine works, although other H2 blockers such as ranitidine, which are stronger than Cemitidine not show the same effect. It has been suggested that Cemitidine exerts effects on the ability of cancer to metastasis. Indeed it was recently discovered that the ability Cemitidine blocks of cancer cells to vascular endothelium in the {} to attach. This leads to a much better result. 84.6% of patients with Duke C colon cancer had a remarkable ten years survival rate, compared to 23.1% of patients who had been given no Cemitidine.
Cemitidine disrupts distribution.
Adhesive molecules are arranged on the surface of many different cell types to provide the adhesion to other cells. These molecules play an important role in many biological processes, including wound healing, immune responses and cancer metastasis.
Celcirculatie in the blood can not circulate without the process to stop at a desired location so as to perform the desired function. For a lymphociet means that it has the ability to go to an infection to go there to take effect. The same applies to a cancer cell to attach and spread in an area, it must first attach to a blood vessel. One of the adhesion molecules, so calledE-selectin. Cimetidine can block the adhesion process.
Conclusion
The beneficial effects of Cemitidine in the treatment of colorectal cancer are well documented. These effects, arising from the multiple performance Cemitidine as H2 receptor antagonist, an immune stimulator and as an adhesion-inhibiting molecule, are not yet approved by the FDA for use against this cancer. Because cimetidine has not been investigated without the combination with the other agent (5-FU), it is unclear whether the effect due to the combination or Cemitidine itself. The proven effectiveness of Cemitidine suggests that it itself is able to prevent some colon cancers grow or to spread. Nevertheless, further research into the effects of single Cemitidine necessary.
Nevertheless, Cemitidine existence in the treatment of cancer, whether alone or in combination used. In 2001 there were 135,000 new cases of colon and rectal cancer, which 56,700 people were dying. If these patients had the science to 800 mg daily Cemitidine to take many of them would have lived.
Note: Tagamet is no longer first choice as a remedy for stomach ulcers or heartburn. Heartburn can be better treated with drugs that completely block the production of stomach acid, such Prolisec, Prevacid and Nexium, an ulcer while treatable with antibiotics, which kill H-pylori bacteria.
Source: PubMed
Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis X and sialyl Lewis-A epitope expression on tumor cells.
Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T.
Department of Surgery, Second Teaching Hospital, School of Medicine, Fujita Health University, 03/06/1910 Otohbashi, Nakagawa-ku, Nagoya 454-8509, Japan. smatsumo@fujita-hu.ac.jp
Cimetidine Has Been Shown to have beneficial effects in colorectal cancer patients. In this study, a total of 64 colorectal cancer patients who Received Curative Operation Were Examined for the effects of cimetidine treatment on survival and Recurrence. Given the cimetidine group was 800 mg day (-1) or cimetidine orally together with 200 mg day (-1) or 5-fluorouracil, while the control group Received 5-fluorouracil alone. The treatment was initiated 2 weeks after the operation and terminated after 1 year. Robust beneficial effects of cimetidine Were noted: the 10-year survival rate of the cimetidine group was 84.6% whereas That of control group was 49.8% (P <0.0001). Accor ding to our previous observations That cimetidine blocked the expression of E-selectin on vascular endothelium and inhibited the adhesion of cancer cells to the endothelium, we have Further stratified The Patient According To the expression levels of sialyl Lewis antigens X (sL (x)) and A (sL (a)). That we found cimetidine treatment was effective in patiënten Particularly Whose tumor had higher sL (x) and sL (a) antigen levels. For example, the 10-year cumulative survival rate of the cimetidine group with higher CSLEX staining, Recognize sL (x) or tumoren was 95.5%, whereas That of control group was 35.1% (P = 0.0001). In contrast, in the Group of Patients with no or low levels CSLEX staining, cimetidine did not show significant beneficial effect (the 10-year survival rate of the cimetidine group was 70.0% and That of control group was 85.7% (P = ns) ). These results Clearly Indicating That Dramatically cimetidine treatment improved survival in colorectal cancer patients with tumor cells expressing high levels of sL (x) and sL (a). Copyright 2002 The Cancer Research Campaign
PMID: 11870500 [PubMed - indexed for MEDLINE]
References of articles and studies cemetidine:
1. Tonnes H, Knigge U, Bulow S, Damm P, K Fischerman, Hesselfeldt P Hjortrup A, Pedersen IK, Pedersen VM, Siemssen OJ. Effect of cimetidine on survival after gastric cancer. Lancet 1988 Oct 29; 2 (8618) :990-2.
2. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet. 24 to 31 December 1994, 344 (8939-8940) :1768-9.
3. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis X and sialyl Lewis-A epitope expression on tumor cells. Brit J Can 2002 (1986) 161-167.
4. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T. Cimetidine inhibits cancer cell adhesion to endothelial cells and Prevents Metastasis by Blocking E-selectin expression. Cancer Res. 2000 in July 1915, 60 (14) :3978-84.
5. Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut November 1994, 35 (11) :1632-6.
6. Siegers CP, DM Hiltl, R. Stich Cimetidine hemmt das Tumorzellwachstum. Therapy Week. 1995 (1936) 2110-2114.
7. Melmon KL, Bourne HR, Weinstein Y, Sela MD. Receptors for histamine can-be detected on the surface of selected leukocytes. Science 1972 (177) 707.
8. Rocklin RE, Greineder DK, Melmon KL. Histamine induced suppressor factor (HSF) Further studies on the nature of the stimulus and the cell Which produces it. Cell Immunol 1979 (1944) 404-415.
9. Hansbrough J, Zapata-Sirvent R, Bender E. Prevention of post-operative Alterations in lymphocyte subpopulations by cimetidine and ibuprofen. Am J Surg 1986 151, 249-255.
10. W. Adams Cimetidine preserves immune function after resection of colonic cancer. Aust. NZ J. Surg 1994 64, 847-852.
11. Adams WJ, Lawson JA, Nicholson SE, Cook TA, Morris DL. The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol 1993 Aug; 19 (4) :332-5.
12. Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R. From Dukes through Jass: Pathological Prognostic indicators in rectal cancer. Hum. Path. 1994 (1925) 495-498.
13. Morris DL, Adams WJ. Cimetidine and colorectal cancer-old drug, new use? Nat Med. December 1995, 1 (12) :1243-4.
14. Uchida A. Biological significance of autologous tumor killing activity and Its induction therapy. Cancer Immun. Immunother 1993 (1937) 1975-1983.
15. American Cancer Society website - Statisticssection.
